Related Experiment Videos
Erythropoietin in pediatric cardiac surgery: clinical efficacy and effective dose
H Shimpo1, T Mizumoto, K Onoda
1Department of Thoracic and Cardiovascular Surgery, Mie University, School of Medicine, Tsu, Japan.
Insights
Erythropoietin (EPO) effectively reduced the need for blood transfusions in pediatric open heart surgery patients. A higher dose of EPO (300 U/kg) showed the best results in avoiding transfusions.
Area of Science:
- Pediatric Surgery
- Hematology
- Pharmacology
Background:
- Pediatric open heart surgery often necessitates blood transfusions.
- Erythropoietin (EPO) is a potential therapeutic agent to mitigate transfusion requirements.
Purpose of the Study:
- To assess the clinical efficacy of erythropoietin (EPO) in children undergoing open heart surgery without transfusion.
- To determine the effective dose of EPO for this patient population.
Main Methods:
- A randomized controlled trial involving 48 children scheduled for open heart surgery without transfusion.
- Three groups were established: high-dose EPO (300 U/kg), low-dose EPO (150 U/kg), and a control group without EPO.
- EPO was administered multiple times, starting before surgery and continuing post-operatively.
Main Results:
- Patients receiving EPO (both doses) exhibited significantly higher hemoglobin concentrations and reticulocyte counts post-surgery compared to the control group.
- The transfusion-free surgery rates were 100% for the high-dose EPO group, 90.9% for the low-dose EPO group, and 68.8% for the control group.
- No adverse reactions were reported with EPO administration.
Conclusions:
- Erythropoietin (EPO) is an effective adjuvant therapy for reducing blood transfusions in pediatric open heart surgery.
- A higher dosage of EPO (300 U/kg) appears to be more effective in achieving transfusion-free outcomes in pediatric patients.
Abstract:
We assessed the clinical efficacy and determined the effective dose of erythropoietin (EPO) in 48 children scheduled for open heart surgery without blood transfusion. The children were divided into three groups: group 1 (n=21) was treated with 300 U/kg of EPO; group 2 (n=11) was treated with 150 U/kg of EPO; and group 3 (n=16) was not treated with EPO. EPO was administered on the day of hospital admission (6 to 7 days prior to surgery), on the following day, immediately after surgery, and on the following day. Immediately after surgery, the hemoglobin concentration in groups 1 and 2 was significantly higher than that in group 3. The reticulocyte count in groups 1 and 2 was significantly higher than that in group 3. Open heart surgery was completed without transfusion in all 21 patients in group 1 (100%), 10 of 11 in group 2 (90.9%), and 11 of 16 in group 3 (68.8%). EPO caused no adverse reactions. In conclusion, EPO was effective as an adjuvant therapy for open heart surgery without blood transfusion in children. Administration of a relatively high dose of EPO (300 U/kg) seems to be effective for pediatric patients.